Based on these preclinical data demonstrating synergy of palbociclib in combination with everolimus, and the demonstrated tolerability of palbociclib in patients with advanced lung cancer, a clinical trial with combined CDK4/6 and mTOR inhibition is warranted. The gene discussed is CDK4; the disease is lung cancer.